At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy of MC5-A ("Scrambler") Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Phase II Pilot Trial
In Brief
A Phase 2 clinical trial evaluating questionnaire administration, Sensory Neuropathy Scale instrument, and 2 other interventions for Chemotherapeutic Agent Toxicity and 4 related conditions. Completed, enrolled 18 participants.
Detailed Summary
RATIONALE: Electronic stimulation using a MC5-A Scrambler may help relieve pain in patients who develop peripheral neuropathy while undergoing chemotherapy treatments for cancer. PURPOSE: This phase II trial is studying how well MC5-A Scrambler therapy works in reducing peripheral neuropathy caused by chemotherapy.
Study Details
Timeline
Interventions
Pain Rating Score
ECOG Common Toxicity Criteria for Sensory Neuropathy scale
Uniscale 0-100 scale global quality of life
Electrical stimulation for 60 minutes